help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Winkler, K.
Right arrow Articles by Zahradnik, H. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Winkler, K.
Right arrow Articles by Zahradnik, H. P.
The Journal of Clinical Endocrinology & Metabolism Vol. 85, No. 12 4543-4550
Copyright © 2000 by The Endocrine Society


Original Studies

Low Density Lipoprotein (LDL) Subfractions during Pregnancy: Accumulation of Buoyant LDL with Advancing Gestation

Karl Winkler, Birgit Wetzka, Michael M. Hoffmann, Isolde Friedrich, Martina Kinner, Manfred W. Baumstark, Heinrich Wieland, Winfried März and Hans Peter Zahradnik

Departments of Clinical Chemistry (K.W., M.M.H., I.F., H.W., W.M.), Obstetrics and Gynecology (B.W., M.K., H.P.Z.), and Sports Medicine (M.W.B.), University of Freiburg, D-79106 Freiburg, Germany

Address all correspondence and requests for reprints to: Karl Winkler, M.D., Department of Clinical Chemistry, Albert Ludwigs University School of Medicine, Hugstetter Strasse 55, D-79106 Freiburg, Germany. E-mail: kwinkler{at}ukl.uni-freiburg.de


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Pregnancy is accompanied by changes in the maternal lipoprotein metabolism that may serve to satisfy the nutritional demands of the fetus. In this study lipoprotein metabolism was investigated in 23 women during normal pregnancy in the first, second, and third trimesters and in 15 healthy nonpregnant women with regular menstrual cycles. Lipid and apolipoprotein concentrations were measured in total plasma, very low density, intermediate density, low density (LDL), and high density lipoproteins, and in each of six LDL subfractions. During early pregnancy, triglycerides, and dense LDL were higher than in the nonpregnant state. With advancing gestation, triglycerides increased and the distribution of apolipoprotein B-100-containing lipoproteins became increasingly dominated by the accumulation of very low density and intermediate density lipoproteins and buoyant, triglyceride-rich LDL. This is the first study that investigates LDL subfractions in pregnancy using a method that strictly separates LDL subfractions by virtue of density. The accumulation of buoyant, triglyceride-rich lipoproteins may be related to the down-regulation of maternal lipase activities by placental hormones. As a consequence, the metabolic changes of late pregnancy may result in an increased flux of lipoprotein-derived lipids to the placenta, which, with advancing gestation, increasingly expresses receptors with a high affinity for triglyceride-rich lipoproteins.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
DURING PREGNANCY maternal metabolism must satisfy the demands of the developing fetus in addition to the energy requirements of the mother. Early pregnancy is considered the anabolic phase, characterized by increased hepatic production of triglycerides and enhanced removal of triglycerides from the circulation, resulting in an increased deposition of fat in maternal adipose tissue. In contrast, late pregnancy is referred to as the catabolic phase; the release of free fatty acids from adipocytes is enhanced due to both relative insulin resistance and stimulation of hormone-sensitive lipase by placental hormones. These metabolic changes allow the metabolism of the gravid female to store energy in early pregnancy to meet the energy requirements of late gestation (1).

As a consequence, the maternal lipid metabolism is specifically altered during pregnancy. Cholesterol and phospholipids increase moderately, whereas plasma triglyceride levels rise markedly (2, 3). High amounts of triglycerides are not only found in the very low density lipoprotein (VLDL) fraction, but in all lipoprotein fractions [low density lipoprotein (LDL) and high density lipoprotein (HDL)] during late gestation (4, 5). Two mechanisms specific for pregnancy seem to be responsible for this phenomenon. First, elevated estrogen levels during gestation result in an increased hepatic synthesis of triglyceride-rich VLDL (6, 7). Secondly, removal of lipoprotein triglycerides is reduced due to low activities of lipoprotein lipase (LPL) and hepatic triglyceride lipase (HL), the effect being more striking for HL than for LPL (8, 9, 10). The abundance of VLDL triglycerides drives an accelerated transfer of triglycerides to lipoproteins of higher density by the cholesteryl ester transfer protein (CETP) (11, 12). Thus, the reduced HL activity appears to be responsible for the shift of HDL subclasses toward larger, triglyceride-rich, and more buoyant species in late gestation (9).

During gestation, LDL particles become enriched in triglycerides as well. However, in contrast to HDL particles, LDL particles have been reported to become smaller and denser (10, 13, 14). LDL particles are heterogeneous with regard to their chemical and physical properties (15, 16). Using nondenaturing gradient gel electrophoresis, Austin et al. (17) demonstrated that two patterns of LDL subclass distribution, A and B, can be distinguished. Pattern A is characterized by a predominance of LDL particles that are large and buoyant, and pattern B is characterized by a predominance of small, dense LDL particles (18). The larger, more buoyant subclasses of LDL predominate in healthy females of reproductive age, whereas smaller, denser LDL often occur after menopause (19). Compared with large and buoyant LDL, small dense LDL particles are more susceptible to oxidation, show increased binding to proteoglycans of the vessel wall, and exhibit reduced uptake by the LDL receptor (20). In men and nonpregnant women, plasma triglycerides account for 40–60% of the variability in small, dense LDL concentrations (21, 22, 23). Several studies have shown there to be an association between elevated plasma triglyceride concentrations, small dense LDL (pattern B) (24, 25, 26) and decreased HDL cholesterol (25, 27), in particular HDL2 cholesterol (24). This metabolic situation is referred to as atherogenic lipoprotein phenotype (24). Thus, elevated triglycerides and the accumulation of small, dense LDL during pregnancy are thought to increase the risk for endothelial damage (28, 29) despite the fact that there is a preponderance of large, buoyant HDL in late gestation (9, 13).

To address the question whether lipid metabolism during pregnancy is indeed similar to that described for the atherogenic lipoprotein phenotype, we examined LDL subfractions by equilibrium density gradient ultracentrifugation during gestation. By including 23 pregnant women, this study is the largest prospective study investigating LDL subfractions.


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Patients and study protocol

Twenty-three pregnant women were studied three times during their visits to the prenatal clinic during the first, second, and third trimesters. The women were not sampled in a defined nutritional status, because fasting conditions are not well tolerated during pregnancy. The control group included 15 healthy, nonpregnant women with regular menstrual cycles. None of the subjects was receiving medication known to influence lipid metabolism. Blood samples were taken from the control group in the midluteal phase when, in the case of conception, implantation takes place and pregnancy begins. This study was approved by the ethics review committee of the University of Freiburg. Informed consent was obtained from each subject, and all procedures were in accordance with the Helsinki Declaration of 1975, revised in 1983.

Lipoprotein separation

Lipoproteins were isolated by sequential preparative ultracentrifugation using the following densities: density less than 1.006 kg/L for VLDL, density between 1.006–1.019 for intermediate density lipoprotein (IDL), density between 1.019–1.063 kg/L for LDL, and density between 1.063–1.21 for HDL (30). LDL subfractions were separated according to the method of Baumstark et al. (31). Total LDL (density, 1.019–1.063 kg/L) were fractionated into six density classes by equilibrium density gradient centrifugation. Density ranges of the subfractions were: LDL-1, less than 1.031 kg/L; LDL-2, 1.031–1.034 kg/L; LDL-3, 1.034–1.037 kg/L; LDL-4, 1.037–1.040 kg/L; LDL-5, 1.040–1.044 kg/L; and LDL-6, more than 1.044 kg/L. All centrifugation steps were carried out at 18 C using partially filled polycarbonate bottles (6 mL) in a 50-Ti rotor. Variability in LDL subfractions with respect to nutritional status were assessed in 5 probands sampled after an overnight fast, 3 h after breakfast, and 3 h after lunch. The average of the intraindividual coefficients of variance (CVs) of each individual for apolipoprotein B (apoB) were 9.6% and 10.2% for VLDL and IDL, and 4.4%, 5.0%, 4.2%, 2.5%, 3.6%, and 3.2% for LDL-1 through LDL-6, respectively. In addition, 6 females were sampled longitudinally in the luteal phase over an average period of 52 ± 30 days, ranging from 24–108 days. Each individual was sampled 2–4 times, and the average of the intraindividual CVs for apoB were 28.0% and 28.1% for VLDL and IDL, and 7.3%, 8.8%, 7.5%, 5.4%, 6.7%, and 8.9% for LDL-1 through LDL-6, respectively.

Lipoprotein chemistry

Cholesterol (CH), free cholesterol, triglycerides (TG), and phospholipids (PL) were determined enzymatically with the CHOD-PAP, GPO-PAP, and PLD-PAP methods (Roche Diagnostics, Mannheim, Germany), respectively. The concentration of esterified cholesterol (CE) was calculated as the difference between total cholesterol and free cholesterol. Concentrations of apolipoproteins were determined by turbidimetry on a Wako 30R analyzer (Wako Chemicals, Tokyo, Japan) using specific polyclonal antisera (Rolf Greiner Biochemica, Frickenhausen, Germany) for the respective antigen. The interassay CVs ranged between 1.0–6.6% for the lipid measurements and between 2.4–8.0% for the apoprotein measurements, respectively.

Particle radius

Lipoprotein radii were calculated using the molar concentrations of free cholesterol, cholesterol esters, phospholipids, triglycerides, and apoB-100 of the respective density fractions (31).

CETP activity

The activity of the cholesteryl ester transfer protein was measured with a fluorescence-based assay (Diagnescent Technologies, Inc., Bronxville, NY). The interassay CV was below 10.0%.

Estradiol

Estradiol levels were determined with a commercial RIA (Biochem Immunosystems GmbH, Freiburg, Germany). The interassay CV was 7.5%.

Statistical analysis

Differences between the luteal phase (control group) and the first, second, and third trimesters were tested for significance using the nonparametric, unpaired Kruskal-Wallis method of one-way ANOVA on ranks. Comparisons between groups were performed using Dunn’s test. Comparisons of each of the three trimesters vs. the control group were made using Dunn’s method vs. the control as indicated. Differences between groups were considered significant at P < 0.05.


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Pregnant women were investigated during routine check-ups in approximately the 12th, 22nd, and 34th week of gestation (Table 1Go). All women had uncomplicated pregnancies and gave birth, on the average, at week 39.5 ± 1.4. The average birth weight of the babies was 3569 ± 484 g. Both control and pregnant groups included only Caucasian women. There was no difference between the control group and the pregnant group before the onset of pregnancy with regard to age and body mass index (Table 1Go).


View this table:
[in this window]
[in a new window]
 
Table 1. Patient’s characteristics and gestational age

 
As expected, significant increases in total cholesterol and total triglycerides were observed with advancing gestation, accompanied by a significant increase in apoB concentrations, the major apoprotein constituent of VLDL, IDL, and LDL. ApoA-I levels were significantly elevated in the second and third trimesters, reaching their highest levels in the second trimester. This was also observed with apoA-II, but the increase was not significant. ApoC-II and apoC-III increased, but only the rise in apoC-III levels was significant. There was a nonsignificant increase in apoE. Lipoprotein(a) did not change during pregnancy (Table 2Go).


View this table:
[in this window]
[in a new window]
 
Table 2. Lipids and apolipoproteins in the nonpregnant state and in the different trimesters of pregnancy

 
Both VLDL-CH and VLDL-TG increased significantly during gestation, with a significant increase in VLDL-apoB concentrations. The ratio of triglycerides to apoB in VLDL steadily decreased with advancing gestation (Table 3Go). Similarly, the concentrations of IDL-CH, IDL-TG, and IDL-apoB rose significantly, with the greatest increase observed from the second to the third trimester (Table 4Go). LDL-CH, LDL-TG, and LDL-apoB were significantly higher in the first trimester compared with the nonpregnant state and showed a further increase as gestation advanced (Table 5Go).


View this table:
[in this window]
[in a new window]
 
Table 3. Composition of VLDL in the nonpregnant state and in the different trimesters of pregnancy

 

View this table:
[in this window]
[in a new window]
 
Table 4. Composition of IDL in the nonpregnant state and in the different trimesters of pregnancy

 

View this table:
[in this window]
[in a new window]
 
Table 5. Composition of LDL in the nonpregnant state and in the different trimesters of pregnancy

 
The density distribution of apoB-100-containing lipoproteins in the nonpregnant control group compared with that in the pregnant group is shown in Fig. 1Go. Each apoB-100-containing lipoprotein possesses only one apoB-100 molecule. The concentration of apoB-100 in each density fraction, therefore, represents the number of lipoprotein particles present in this particular fraction. Compared with the nonpregnant state, the concentration of LDL-2 was low in the first trimester, whereas the concentration of LDL-6 was significantly higher. The concentration of the LDL-6 fraction maintained virtually the same level in the second and third trimesters. In the second trimester the concentrations of VLDL, IDL, and LDL-1 through LDL-5 further increased, producing a distribution of lipoproteins dominated by buoyant lipoprotein species, namely VLDL, IDL, and in particular LDL-1. Toward delivery VLDL, IDL, and LDL-1 increased even further, with the concentration of LDL-1 clearly dominating. LDL particles became significantly enriched in triglycerides, as indicated by the molar ratio of triglycerides to apoB in LDL (Table 5Go). This was also observed for each of the LDL subfractions (Fig. 2Go). The increase in LDL-TG was accompanied by significant decreases in the cholesterol and phospholipid content per LDL particle thus resulting in a decrease of the average particle size of LDL (Table 5Go). The decrease in particle size was also observed in each of the LDL subfractions, the difference of LDL-3 being statistically significant compared with the nonpregnant control group (Fig. 3Go).



View larger version (18K):
[in this window]
[in a new window]
 
Figure 1. Concentrations of apoB in VLDL, IDL, and the LDL subfractions in the nonpregnant state and in the different trimesters of pregnancy. V, I, L-1 through L-6, VLDL, IDL, and LDL-1 through LDL-6, respectively. {circ}, Luteal phase; •, first trimester; {blacktriangleup}, second trimester; {blacksquare}, third trimester. By ANOVA: a, P < 0.05 vs. luteal phase; b, P < 0.05 vs. first trimester; c, P < 0.05 vs. second trimester.

 


View larger version (18K):
[in this window]
[in a new window]
 
Figure 2. TG content per LDL subfraction particle in the nonpregnant state and in the different trimesters of pregnancy. L-1 through L-6, LDL-1 through LDL-6, respectively. {circ}, Luteal phase; •, first trimester; {blacktriangleup}, second trimester; {blacksquare}, third trimester. By ANOVA: a, P < 0.05 vs. luteal phase; b, P < 0.05 vs. first trimester; c, P < 0.05 vs. second trimester.

 


View larger version (16K):
[in this window]
[in a new window]
 
Figure 3. Calculated radii of LDL subfractions in the nonpregnant state and the different trimesters of pregnancy. L-1 through L-6, LDL-1 through LDL-6, respectively. {circ}, Luteal phase; •, first trimester; {blacktriangleup}, second trimester; {blacksquare}, third trimester. *, P < 0.05 for all trimesters using Dunn’s method vs. the control group.

 
High density lipoprotein cholesterol levels did not change substantially during pregnancy. In contrast, HDL-TG were significantly higher in the first trimester compared with the nonpregnant state and continued to increase toward the end of pregnancy. Similarly, apoA-I, the structural apoprotein of HDL, increased significantly. The molar ratio of triglycerides to apoA-I was almost 3 times higher in the third trimester compared with the luteal phase, indicating that HDL became highly enriched with triglycerides (Table 6Go).


View this table:
[in this window]
[in a new window]
 
Table 6. Composition of HDL in the nonpregnant state and in the different trimesters of pregnancy

 
Figure 4Go shows the ratio of CE to TG in VLDL (A), IDL (B), LDL (C), and HDL (D) plotted vs. the time of gestation. Regression analysis revealed that the VLDL-CE/TG-ratio correlated significantly (r = 0.223; P = 0.047) with the time of gestation. The IDL-CE/TG ratio did not correlate (r = 0.073); however, there was a tendency toward increased values with advancing gestation. In striking contrast, the CE/TG ratios of LDL (r = -0.726; P < 0.0001) and HDL (r = -0.713; P < 0.0001) were inversely correlated with the time of gestation.



View larger version (33K):
[in this window]
[in a new window]
 
Figure 4. A—D, Correlation of VLDL-, IDL-, LDL-, and HDL-CE/TG vs. time of gestation. A, VLDL; B, IDL; C, LDL; D, HDL. R, Correlation coefficient. Levels of significance: *, P < 0.05; **, P < 0.01; ***, P < 0.001.

 
As expected, estradiol levels rose during gestation; the changes were significant in the second and third trimesters (Table 7Go). Compared with the luteal phase, the concentration of free fatty acids was higher in the first trimester and increased continuously toward the end of pregnancy, although none of these changes was significant (Table 7Go). As previously described (9), the activity of CETP increased during pregnancy, but none of the changes was significant (Table 7Go).


View this table:
[in this window]
[in a new window]
 
Table 7. Estradiol and free fatty acid levels and CETP activity in the nonpregnant state and in the different trimesters of pregnancy

 

    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Estradiol concentrations as well as free fatty acid levels rose continuously throughout pregnancy. The enhanced availability of substrates for TG synthesis allows estrogen to stimulate the release of VLDL-TG (9). Consistent with earlier studies (32, 33), this resulted in a steady increase in total TG, total CH, and total apoB with the time of gestation. In agreement with the literature (9, 10, 13, 34), this was also true for VLDL, IDL, and LDL. However, this contrasts with the situation in nonpregnant women and men, in whom higher concentrations of plasma TG are associated with preferentially higher VLDL concentrations only (23).

Blood samples were not drawn under defined nutritional conditions. However, the impact of nutrition on the variability of LDL subfractions was on the order of the interassay variability in apoB and may, therefore, be neglected. This was an expected finding, as LDL have a residence time of several days. Thus, short-term disturbances of apoB metabolism such as nutrition are not likely to influence LDL subfraction distribution. Compared to nonpregnant women, LDL-6, the densest LDL subfraction, was significantly higher in the first trimester and remained at this same level throughout pregnancy. However, with advancing gestation, the LDL distribution pattern became increasingly dominated by triglyceride-rich lipoproteins, namely VLDL, IDL, and in particular the most buoyant LDL (LDL-1) in the 2nd and 3rd trimesters. This was an unexpected finding, because the few previous studies reported the preponderance of small, dense LDL throughout all stages of pregnancy, including late gestation (10, 13, 14). Using nondenaturing PAGE, Silliman et al. (13) studied 36 Hispanic women in the 36th week of gestation. Among these, 1 individual showed pattern A (mainly large LDL), 18 showed the intermediate pattern I, and 17 showed pattern B (mainly small LDL). Using the same method, Hubel et al. (14) investigated the LDL peak particle diameter on 4 occasions during pregnancy and twice postpartum. In 7 of 10 women a progressive decrease in LDL particle size was seen during normal gestation as TG increased, followed by the reversal of these changes by 6–12 weeks postpartum. Sattar et al. (10) used nonequilibrium density gradient ultracentrifugation to separate LDL by flotation rate into 3 subfractions (LDL-I, LDL-II, and LDL-III) (35) at 5-week intervals between the 10th and 35th week of gestation. In 6 of 10 women an increase in LDL-III mass at the expense of LDL-II was reported, with the proportion of LDL-I remaining unchanged. However, in the other four subjects no change in the LDL subfraction pattern occurred throughout gestation.

The overt discrepancy between the previously published data and the observations reported here may be due to the different methodology used. Nondenaturing gradient gel electrophoresis separates LDL by virtue of size and provides an estimate of the particle diameter of the major LDL peak (17). The density gradient ultracentrifugation used by Sattar et al. does not reach isopycnic equilibrium (35) and therefore separates LDL by virtue of flotation rate. Flotation rate depends on both particle buoyancy and the size of the particle. It thus appears that all studies conducted previously examined the LDL subfraction profile with methods depending more or less on particle size. In contrast, the method used in this study relies upon equilibrium density gradient ultracentrifugation, which separates LDL subfractions by virtue of their density (31).

The increase in TG per LDL particle with the decrease in cholesterol and phospholipid content at the same time suggests that a change in the size of a lipoprotein particle may not necessarily be accompanied by a matching change in density. To address this possibility, we calculated the radii of the LDL particles from the lipid and apolipoprotein compositions measured in each of the separated LDL subfractions (31). The particle size of all LDL subfractions continuously decreased between the luteal phase and the third trimester; the change in the LDL-3 fraction was significant compared with that during the luteal phase. As LDL-3 particles are medium in density and in size, the changes in size seen in this fraction may correspond to the changes in the peak LDL particle diameters reported by Silliman and Hubel (13, 14), in agreement with our findings.

What is the mechanism underlying the changes of lipoprotein metabolism observed during pregnancy? As previously discussed (10, 13, 14), the elevated TG levels already present in the first trimester may be responsible for the increase in dense LDL seen during the early stages of pregnancy. However, with advancing gestation there is no further increase in dense LDL. In contrast, there is an increase in buoyant lipoproteins, namely VLDL, IDL, and LDL-1, a pattern closely resembling the situation in HL deficiency. HL has been reported to be involved in the conversion of IDL to LDL (36, 37), in chylomicron remnant catabolism (38, 39), and in HDL metabolism (40, 41). Impaired HL activity results in elevated HDL2-CH (42, 43, 44) and an enrichment of LDL and HDL particles with triglycerides (43, 44, 45).

Alvarez et al. (9) investigated the HDL metabolism of 25 pregnant women during gestation and postpartum. The TG/CH ratio in both LDL and HDL was shown to increase due to the activity of CETP, although the CETP activity did not increase significantly with advancing gestation. Similar observations were made in the present study. Although not analyzed here, the enrichment of HDL particles with TG is likely to represent an increase in the more buoyant HDL2 particles. This is in line with studies that showed that the increase in HDL during late pregnancy is associated with a dramatic increase in the most buoyant HDL species, HDL2b, and a significant decrease in HDL3 levels (11). In the study by Alvarez et al., the postheparin HL activity progressively decreased after the first trimester throughout pregnancy and was significantly correlated with the changes in the HDL subclasses (9). In addition, HL activity was negatively correlated with estradiol levels (9), which is in line with other studies indicating that elevated estrogen concentrations are associated with decreased HL activities (8, 10, 46). The significant increase in apoC-III, an inhibitor of LPL, may also contribute to the impairment of maternal lipolysis. As a consequence this may delay the turnover and increase the residence time of TG-rich lipoproteins. The prolonged exposure of these lipoproteins to CETP rather than elevated activities of CETP might, therefore, be responsible for the observed compositional changes: VLDL and IDL particles become enriched in CE, whereas LDL and HDL particles become enriched in triglycerides. Thus, in late pregnancy, the observed changes in lipoprotein composition may reflect a reduced catabolism of TG-rich lipoproteins. In contrast, treatment with low doses of estrogen as in hormone replacement therapy (47) or hormonal contraception (48) results in an increased production of large, TG-rich VLDL only, whereas VLDL catabolism is not affected.

What may be the implications of the metabolic changes reported here for the physiology of pregnancy? Sattar et al. (49) found that in mothers with intrauterine growth retardation the appropriate synthesis of LDL precursors, namely VLDL and IDL, fails to occur in the third trimester. This suggests that in late gestation the welfare of the unborn child depends on an adequate supply of lipids. In the fetus, longer chain essential fatty acids are synthesized by the liver and the brain from linoleic acid and {alpha}-linolenic acid, which are provided by the mother (50). Free fatty acids are transferred across the placenta by simple diffusion (51, 52). However, the capacity of this transport is limited. Therefore, the increasing requirements of the fetus in late gestation need to be satisfied by additional means. Human placenta is known to express lipoprotein receptors in high amounts (53, 54). Interestingly, the binding of VLDL to placental membranes exceeds that of LDL, suggesting that the placenta is primarily endowed with receptors that preferentially bind to VLDL (55). In this regard, the VLDL/apoE receptor appears to be of particular interest. The localization and regulation of this receptor suggest a major role in placental lipid transport. Northern blot analysis of placenta revealed a 2.6-fold increase in VLDL/apoE receptor messenger ribonucleic acid between the first trimester and delivery (54). Thus, in the catabolic phase of pregnancy, the effect of placental hormones is to enhance VLDL production and decrease HL activity. Together with the increased expression of the VLDL/apoE receptor in the placenta, this may result in a coordinated rerouting of the swelling flux of TG-rich lipoproteins from the mother to the feto-placental unit (Fig. 5Go).



View larger version (23K):
[in this window]
[in a new window]
 
Figure 5. Metabolism of apoB-containing lipoproteins in late pregnancy. FFA, Free fatty acids; TG, triglycerides; CE, cholesteryl-esters; V, VLDL; I, IDL; L-1, L-3, and L-6, represent all LDL subfractions, namely LDL-1 through LDL-6; LPL, lipoprotein lipase; HL, hepatic triglyceride lipase; CETP, cholesterol-ester transfer protein.

 
In conclusion, our data do not support the idea that the same mechanisms as those described for the atherogenic lipoprotein phenotype govern lipid metabolism in late pregnancy. The changes in VLDL, IDL, and HDL metabolism together with the compositional changes and the changes in the subfraction profile of LDL presented in this study are compatible with the well established reduction of hepatic TG lipase activity during pregnancy. Patients suffering from familial (44, 56) or acquired (57) forms of HL deficiency accumulate large, buoyant LDL-like particles that are enriched in TG and depleted in CE, as shown for late pregnancy in this study. Interestingly, these individuals may present with characteristics similar to those of type III hyperlipoproteinemia and are prone to develop premature cardiovascular disease (45, 58). Therefore, we postulate that even on the basis of a mechanism different from the atherogenic lipoprotein phenotype, pregnancy may still put women at risk for vascular damage. In uncomplicated pregnancies there appears to be a balance between potentially damaging factors such as altered lipid metabolism and as yet poorly understood protective mechanisms (59, 60). However, the clinical significance of gestational lipoprotein metabolism may arise if this balance is compromised as in hypertensive disorders of pregnancy.


    Acknowledgments
 
We are grateful to Beatrice Lederle for clinical support, Wolfgang Schäfer for the measurement of estrogen, Hubert Scharnagl and Ursula Tisljar for valuable discussion, and Jeanne Strepacki for editing the manuscript.

Received December 30, 1999.

Revised June 6, 2000.

Revised August 15, 2000.

Accepted August 30, 2000.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Stock MJ, Metcalfe J. 1994 Maternal physiology during gestation. In: Knobil E, Neill JD, eds. The physiology of reproduction. New York: Raven Press; 947–983.
  2. Boyd EM. 1934 The lipemia of pregnancy. J Clin Invest. 13:347–363.
  3. Peters JP, Heinemann M, Man EB. 1951 The lipids of serum in pregnancy. J Clin Invest. 30:388–394.
  4. Montelongo A, Lasuncion MA, Pallardo LF, Herrera E. 1992 Longitudinal study of plasma lipoproteins and hormones during pregnancy in normal and diabetic women. Diabetes. 41:1651–1659.[Abstract]
  5. Knopp RH, Bonet MA, Lasuncion A, Montelongo A, Herrera E. 1992 Lipoprotein metabolism in pregnancy. In: Herrera E, Knopp RH, eds. Perinatal biochemistry. Boca Raton: CRC Press; 19–51.
  6. Julius U, Fritsch H, Fritsch W, Rehak E, Fücker K, Leonhardt W, Hanefeld M. 1994 Impact of hormone replacement therapy on postprandial lipoproteins and lipoprotein(a) in normolipidemic postmenopausal women. Clin Investig. 72:502–507.[Medline]
  7. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. 1991 Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 325:1196–1204.[Abstract]
  8. Kinnunen PK, Unnerus HA, Ranta T, Ehnholm C, Nikkilä EA, Seppälä M. 1980 Activities of postheparin plasma lipoprotein lipase and hepatic lipase during pregnancy and lactation. Eur J Clin Invest. 10:469–474.[Medline]
  9. Alvarez J, Montelongo A, Iglesias A, Lasuncion MA, Herrera E. 1996 Longitudinal study on lipoprotein profile, high density lipoprotein subclass, and postheparin lipases during gestation in women. J Lipid Res. 37:299–308.[Abstract]
  10. Sattar N, Greer IA, Louden J, et al. 1997 Lipoprotein subfraction changes in normal pregnancy: threshold effect of plasma triglyceride on appearance of small, dense low density lipoprotein. J Clin Endocrinol Metab. 82:2483–2491.[Abstract/Free Full Text]
  11. Silliman K, Tall AR, Kretchmer N, Forte TM. 1993 Unusual high-density lipoprotein subclass distribution during late pregnancy. Metabolism. 42:1592–1599.[CrossRef][Medline]
  12. Iglesias A, Montelongo A, Herrera E, Lasuncion MA. 1994 Changes in cholesteryl ester transfer protein activity during normal gestation and postpartum. Clin Biochem. 27:63–68.[CrossRef][Medline]
  13. Silliman K, Shore V, Forte TM. 1994 Hypertriglyceridemia during late pregnancy is associated with the formation of small dense low-density lipoproteins and the presence of large buoyant high-density lipoproteins. Metabolism. 43:1035–1041.[CrossRef][Medline]
  14. Hubel CA, Shakir Y, Gallaher MJ, McLaughlin MK, Roberts JM. 1998 Low-density lipoprotein particle size decreases during normal pregnancy in association with triglyceride increases. J Soc Gynecol Invest. 5:244–250.[Medline]
  15. Hammand MG, Fisher WR. 1971 The characterization of a discrete series of low density lipoproteins in the disease hyper-pre-ß-lipoproteinemia. J Biol Chem. 246:5454–5465.[Abstract/Free Full Text]
  16. Shen MM, Krauss RM, Lindgren FT, Forte TM. 1981 Heterogeneity of serum low density lipoproteins in normal human subjects. J Lipid Res. 22:236–244.[Abstract]
  17. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. 1988 Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 260:1917–1921.[Abstract]
  18. Austin MA, Hokanson JE, Brunzell JD. 1994 Characterization of low-density lipoprotein subclasses: methodologic approaches and clinical relevance. Curr Opin Lipidol. 5:395–403.[Medline]
  19. McNamara JR, Campos H, Ordovas JM, Peterson JH, Wilson PWF, Schaefer E. 1987 Effect of gender, age, and lipid status on low density lipoprotein subfraction distribution. Arteriosclerosis. 7:483–490.[Abstract/Free Full Text]
  20. Anber V, Griffin BA, McConnell M, Packard CJ, Shepherd J. 1996 Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Atherosclerosis. 124:261–271.[CrossRef][Medline]
  21. Tornvall P, Karpe F, Carlson LA, Hamsten A. 1991 Relationship of low density lipoprotein subfractions to angiographically defined coronary artery disease in young survivors of myocardial infarction. Atherosclerosis. 90:67–80.[CrossRef][Medline]
  22. Griffin BA, Freeman DJ, Tait GW, et al. 1994 Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis. 106:241–253.[CrossRef][Medline]
  23. Tan CE, Forster L, Caslake MJ, et al. 1995 Relations between plasma lipids and postheparin plasma lipases and VLDL and LDL subfraction patterns in normolipemic men and women. Arterioscler Thromb Vasc Biol. 15:1839–1848.[Abstract/Free Full Text]
  24. Austin MA, King MC, Vranizian KM, Krauss RM. 1990 The atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation. 82:495–506.[Abstract/Free Full Text]
  25. Krauss RM. 1991 The tangled web of coronary risk factors. Am J Med. 90:36S–41S.
  26. McNamara JR, Jenner JL, Li Z, Wilson PW, Schaefer EJ. 1992 Change in LDL particle size is associated with change in plasma triglyceride concentration. Arterioscler Thromb. 12:1284–1290.[Abstract/Free Full Text]
  27. Austin MA, Brunzell JD, Fitch WL, Krauss RM. 1990 Inheritance of low density lipoprotein subclass patterns in familial combined hyperlipidemia. Arteriosclerosis. 10:520–530.[Abstract/Free Full Text]
  28. Sattar N, Bendomir A, Berry C, Shepherd J, Greer IA, Packard CJ. 1997 Lipoprotein subfraction concentrations in preeclampsia: pathogenic parallels to atherosclerosis. Obstet Gynecol. 89:403–408.[Abstract]
  29. Hubel CA, Lyall F, Weissfeld L, Gandley RE, Roberts JM. 1998 Small low-density lipoproteins and vascular cell adhesion molecule-1 are increased in association with hyperlipidemia in preeclampsia. Metabolism. 47:1281–1288.[CrossRef][Medline]
  30. Havel RJ, Eder HA, Bragdon JH. 1955 The distribution and chemical composition of ultracentrifugally separated lipoproteins in human plasma. J Clin Invest. 34:1345–1353.
  31. Baumstark MW, Kreutz W, Berg A, Frey I, Keul J. 1990 Structure of human low-density lipoprotein subfractions, determined by x-ray small-angle scattering. Biochim Biophys Acta. 1037:48–57.[CrossRef][Medline]
  32. Williams PF, Simons LA, Turtle JR. 1976 Plasma lipoproteins in pregnancy. Horm Res. 7:83–90.[Medline]
  33. Knopp RH, Bergelin RO, Wahl PW, Walden CE, Chapman M, Irvine S. 1982 Population-based lipoprotein lipid reference values for pregnant women compared to nonpregnant women classified by sex hormone usage. Am J Obstet Gynecol. 143:626–637.[Medline]
  34. Warth MR, Arky RA, Knopp RH. 1975 Lipid metabolism in pregnancy. III. Altered lipid composition in intermediate, very low, low, and high-density lipoprotein fractions. J Clin Endocrinol Metab. 41:649–655.[Abstract]
  35. Griffin BA, Caslake MJ, Yip B, Tait GW, Packard CJ, Shepherd J. 1990 Rapid isolation of low density lipoprotein (LDL) subfractions from plasma by gradient ultracentrifugation. Atherosclerosis. 83:59–67.[CrossRef][Medline]
  36. Jansen H, van Tol A, Hülsmann WC. 1980 On the metabolic function of heparin-releasable liver lipase. Biochem Biophys Res Commun. 92:53–59.[CrossRef][Medline]
  37. Demant T, Carlsson LA, Holmquist L, et al. 1988 Lipoprotein metabolism in hepatic lipase deficiency: studies on the turnover of apolipoprotein B and on the effect of hepatic lipase on high density lipoprotein. J Lipid Res. 29:1603–1611.[Abstract]
  38. Daggy BP, Bensadoun A. 1986 Enrichment of apolipoprotein B-48 in the LDL density class following in vivo inhibition of hepatic lipase. Biochim Biophys Acta. 877:252–261.[Medline]
  39. Shafi S, Brady SE, Bensadoun A, Havel RJ. 1994 Role of hepatic lipase in the uptake and processing of chylomicron remnants in the rat liver. J Lipid Res. 35:709–720.[Abstract]
  40. Kuusi T, Ehnholm C, Viikari J, et al. 1989 Postheparin plasma lipoprotein and hepatic lipase are determinants of hypo- and hyperalphalipoproteinemia. J Lipid Res. 30:1117–1126.[Abstract]
  41. Blades B, Vega GL, Grundy SM. 1993 Activities of lipoprotein lipase and hepatic triglyceride lipase in postheparin plasma of patients with low concentrations of HDL cholesterol. Arterioscler Thromb. 13:1227–1235.[Abstract/Free Full Text]
  42. Breckenridge WC, Little JA, Alaupovic P, et al. 1982 Lipoprotein abnormalities associated with a familial deficiency of hepatic lipase. Atherosclerosis. 45:161–179.[CrossRef][Medline]
  43. Carlson LA, Holmquist L, Nilsson-Ehle P. 1986 Deficiency of hepatic lipase activity in post-heparin plasma in familial hyper-alphatriglyceridemia. Acta Med Scand. 219:435–447.[Medline]
  44. Knudsen P, Antikainen M, Ehnholm S, et al. 1996 A compound heterozygote for hepatic lipase gene mutation Leu334->Phe and Thr383->Met: correlation between hepatic lipase activity and phenotypic expression. J Lipid Res. 37:825–834.[Abstract]
  45. Hegele RA, Little JA, Vezina C, et al. 1993 Hepatic lipase deficiency. Clinical, biochemical, and molecular genetic characteristics. Arterioscler Thromb. 13:720–728.[Abstract/Free Full Text]
  46. Applebaum-Bowden D, McLean P, Steinmetz A, et al. 1989 Lipoprotein, apolipoprotein, and lipolytic enzyme changes following estrogen administration in postmenopausal women. J Lipid Res. 30:1895–1906.[Abstract]
  47. Campos H, Walsh BW, Judge H, Sacks FM. 1997 Effect of estrogen on very low density lipoprotein and low density lipoprotein subclass metabolism in postmenopausal women. J Clin Endocrinol Metab. 82:3955–3963.[Abstract/Free Full Text]
  48. Walsh BW, Sacks FM. 1993 Effects of low dose oral contraceptives on very low density and low density lipoprotein metabolism: J Clin Invest. 91:2126–2132.
  49. Sattar N, Greer IA, Galloway PJ, et al. 1999 Lipid and lipoprotein concentrations in pregnancies complicated by intrauterine growth restriction. J Clin Endocrinol Metab. 84:128–130.[Abstract/Free Full Text]
  50. Bezard J, Blond JP, Bernard A, Clouet P. 1994 The metabolism and availability of essential fatty acids in animal and human tissues. Reprod Nutr Dev. 34:539–568.
  51. Portman OW, Behrman RE, Soltys P. 1969 Transfer of free fatty acids across the primate placenta. Am J Physiol. 216:143–147.[Free Full Text]
  52. Elphick MC, Hull D, Sanders RR. 1976 Concentrations of free fatty acids in maternal and umbilical cord blood during elective caesarean section. Br J Obstet Gynaecol. 83:539–544.[Medline]
  53. Jensen PH, Moestrup SK, Glieman J. 1989 Purification of the human placental {alpha}2-macroglobulin receptor. FEBS Lett. 255:275–280.[CrossRef][Medline]
  54. Wittmaack FM, Gafvels ME, Bronner M, et al. 1995 Localization and regulation of the human very low density lipoprotein/apolipoprotein-E receptor: trophoblast expression predicts a role for the receptor in placental lipid transport. Endocrinology. 136:340–348.[Abstract]
  55. Naoum HG, De-Chazal RC, Eaton BM, Contractor SF. 1987 Characterization and specifity of lipoprotein binding to term human placental membranes. Biochim Biophys Acta. 902:193–199.[Medline]
  56. Auwerx JH, Marzetta CA, Hokanson JE, Brunzell JD. 1989 Large buoyant LDL-like particles in hepatic lipase deficiency. Arteriosclerosis. 9:319–325.[Abstract/Free Full Text]
  57. Goldberg IJ, Mazlen RG, Rubenstein A, et al. 1985 Plasma lipoprotein abnormalities associated with acquired hepatic triglyceride lipase deficiency. Metabolism. 34:832–835.[CrossRef][Medline]
  58. Brand K, Dugi KA, Brunzell JD, Nevin DN, Santamarina-Fojo S. 1996 A novel A->G mutation in intron I of the hepatic lipase gene leads to alternative splicing resulting in enzyme deficiency. J Lipid Res. 37:1213–1223.[Abstract]
  59. Lorentzen B, Henriksen T. 1998 Plasma lipids and vascular dysfunction in preeclampsia. Semin Reprod Endocrinol. 16:33–39.[Medline]
  60. Rodgers GM, Taylor RN, Roberts JM. 1988 Preeclampsia is associated with a serum factor cytotoxic to human endothelial cells. Am J Obstet Gynecol. 159:908–914.[Medline]



This article has been cited by other articles:


Home page
PediatricsHome page
R. J. Edison, K. Berg, A. Remaley, R. Kelley, C. Rotimi, R. E. Stevenson, and M. Muenke
Adverse Birth Outcome Among Mothers With Low Serum Cholesterol
Pediatrics, October 1, 2007; 120(4): 723 - 733.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
C. Wadsack, S. Tabano, A. Maier, U. Hiden, G. Alvino, V. Cozzi, M. Huttinger, W. J. Schneider, U. Lang, I. Cetin, et al.
Intrauterine growth restriction is associated with alterations in placental lipoprotein receptors and maternal lipoprotein composition
Am J Physiol Endocrinol Metab, February 1, 2007; 292(2): E476 - E484.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
W. Marz, H. Scharnagl, K. Winkler, A. Tiran, M. Nauck, B. O. Boehm, and B. R. Winkelmann
Low-Density Lipoprotein Triglycerides Associated With Low-Grade Systemic Inflammation, Adhesion Molecules, and Angiographic Coronary Artery Disease: The Ludwigshafen Risk and Cardiovascular Health Study
Circulation, November 9, 2004; 110(19): 3068 - 3074.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
L. Pavan, A. Hermouet, V. Tsatsaris, P. Therond, T. Sawamura, D. Evain-Brion, and T. Fournier
Lipids from Oxidized Low-Density Lipoprotein Modulate Human Trophoblast Invasion: Involvement of Nuclear Liver X Receptors
Endocrinology, October 1, 2004; 145(10): 4583 - 4591.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
K. Winkler, T. Konrad, S. Fullert, I. Friedrich, R. Destani, M. W. Baumstark, K. Krebs, H. Wieland, and W. Marz
Pioglitazone Reduces Atherogenic Dense LDL Particles in Nondiabetic Patients With Arterial Hypertension: A double-blind, placebo-controlled study
Diabetes Care, September 1, 2003; 26(9): 2588 - 2594.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
V. Vihma, A. Tiitinen, O. Ylikorkala, and M. J. Tikkanen
Quantitative Determination of Estradiol Fatty Acid Esters in Lipoprotein Fractions in Human Blood
J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2552 - 2555.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
K. Winkler, B. Wetzka, M. M. Hoffmann, I. Friedrich, M. Kinner, M. W. Baumstark, H.-P. Zahradnik, H. Wieland, and W. Marz
Triglyceride-Rich Lipoproteins Are Associated with Hypertension in Preeclampsia
J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1162 - 1166.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
J. Wiemer, K. Winkler, M. Baumstark, W. Marz, and J. E. Scherberich
Influence of low molecular weight heparin compared to conventional heparin for anticoagulation during haemodialysis on low density lipoprotein subclasses
Nephrol. Dial. Transplant., December 1, 2002; 17(12): 2231 - 2238.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
K. Winkler, C. Abletshauser, M. M. Hoffmann, I. Friedrich, M. W. Baumstark, H. Wieland, and W. Marz
Effect of Fluvastatin Slow-Release on Low Density Lipoprotein (LDL) Subfractions in Patients with Type 2 Diabetes Mellitus: Baseline LDL Profile Determines Specific Mode of Action
J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5485 - 5490.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Winkler, K.
Right arrow Articles by Zahradnik, H. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Winkler, K.
Right arrow Articles by Zahradnik, H. P.


HOME HELP FEEDBACK SUBSCRIPTIONS